Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Efgartigimod PH20 SC via Autoinjector vs Prefilled Syringe in Healthy Adults
NCT07782775Phase 1Completed
- Sponsor
- argenx
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (2 arms), sponsored by argenx. Primary endpoints: Maximum Observed Plasma Concentration up to 9 weeks and Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity up to 9 weeks. Started Jun 2026; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07782775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782775.